Menu
Question:
Are there any new pass-through drugs for the upcoming quarter?
Answer:
The Centers for Medicare & Medicaid Services (CMS) have granted outpatient prospective payment system (OPPS) pass-through status, effective July 1, 2018 the following drugs and biological:
| C9030 | Injection, copanlisib, 1 mg |
| C9031 | Lutetium Lu 177, dotatate, therapeutic, 1 mCi |
| C9032 | Injection, voretigene neparvovec-rzyl, 1 billion vector genome |
| Q9991 | Injection, buprenorphine extendedrelease (Sublocade), less than or equal to 100 mg |
| Q9992 | Injection, buprenorphine extendedrelease (Sublocade), greater than 100 mg |
| Q9995 | Injection, emicizumab-kxwh, 0.5 mg |
CPT® copyright 2021 American Medical Association (AMA). All rights reserved.
Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
CPT is a registered trademark of the American Medical Association.
Subscribe to receive our News, Insights, and Compliance Question of the Week delivered right to your inbox.
Address: 445 Minnesota Street, Suite 514
St. Paul, MN 55101
Phone: (800) 252-1578
Email: support@medlearnmedia.com
Hours: 9am – 5pm CT
Copyright © 2022 MedLearn Publishing. Powered by MedLearn Media.
